SEC Form 4 · accession 0001610717-26-000360
Ascendis Pharma A/S · ASND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 9:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001612042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 14, 2026 | P | 1,100 | $245.85 | A | 2,000 | D | |
| Ordinary SharesF2 | Aug 14, 2026 | P | 900 | $246.91 | A | 2,900 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.